Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01739439 · ClinicalTrials.gov registry record · Phase 1
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01739439 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT01739439, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of radiosurgery boost following chemoradiation in treating patients with locally advanced pancreatic cancer that may or may not be removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Giving chemotherapy and radiation therapy together with radiosurgery may kill more tumor cells and allow doctors to save the part of the body where the cancer started
Interventions
- RADIATION intensity-modulated radiation therapy
- RADIATION radiosurgery
- PROCEDURE diffusion-weighted magnetic resonance imaging
- DRUG gemcitabine hydrochloride
- RADIATION hyperfractionated radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01739439
The ClinicalTrials.gov registry entry for NCT01739439 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT01739439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01739439 about?
NCT01739439 is a clinical study titled "Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery". This phase I trial studies the side effects and best dose of radiosurgery boost following chemoradiation in treating patients with locally advanced pancreatic cancer that may or may not be removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either...
What is the current status of trial NCT01739439?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-05. Estimated completion is 2015-12-01.
What interventions are being tested in trial NCT01739439?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), radiosurgery (RADIATION), diffusion-weighted magnetic resonance imaging (PROCEDURE), gemcitabine hydrochloride (DRUG), hyperfractionated radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01739439?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.